This collaboration between Eli Lilly and a Top VC fund can redefine how Corporate VC (CVC) fuels innovation – not just in ...

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,020.00. Akash Tewari’s rating is based ...

In the latest trading session, Eli Lilly (LLY) closed at $753.98, marking a +1.57% move from the previous day. This move outpaced the S&P 500's daily gain of 0.61%. Meanwhile, the Dow gained 0.3% ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.

Oak Ridge Investments LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 6.2% during the fourth quarter, according to its most recent Form 13F filing with the ...

Bank of America Securities analyst Tim Anderson maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday at $725.72. According to ...

In this article, we are going to take a look at where Eli Lilly And Co. (NYSE:LLY) stands against other stocks that could split in the near future. Stock splits don’t change how much a company ...

Evercore ISI analyst Umer Raffat maintained a Hold rating on Eli Lilly & Co (LLY – Research Report) yesterday. The company’s shares closed yesterday at $753.98. Raffat covers the Healthcare ...